title: Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation.
abstract: Cytochrome P450 2E1 (CYP2E1) is a phase I detoxification enzyme, which is induced by chronic alcohol consumption. It is involved in the activation of numerous carcinogens and in the production of free radicals. As it has previously been shown to be induced in diabetic and obese rats, the aim of this study was to investigate its induction level in poorly-controlled diabetics and in obese patients (Body Mass Index > 30 kg/m2). CYP2E1 activity was determined in 35 diabetic and 17 obese patients by using the in vivo chlorzoxazone hydroxylation test. Even though the glucidic parameters were highly disturbed (mean fasting glycemia > 7.9 mmol/L, post prandial glycemia > 12.2 mmol/L and fructosamine > 326 mumol/L), CYP2E1 activity was not enhanced either in insulin-dependent diabetics (IDDs, n = 7) nor in non-obese non-insulin-dependent diabetics (NIDDs, n = 15) when compared to controls (n = 42) (0.21 +/- 0.03, 0.33 +/- 0.03 and 0.30 +/- 0.02, respectively, mean +/- SEM). However, this activity was lower in IDDs when compared to NIDDs (P < 0.05). In obese patients, with (n = 13) or without (n = 17) NIDD mellitus, CYP2E1 activity was increased by a mean of 40% when compared to controls. In addition, positive correlations were found in all subjects (controls or patients, n = 74) between CYP2E1 activity and serum cholesterol (r = 0.42, P < 0.0001), triglycerides (r = 0.44, P < 0.0001) and BMI (r = 0.36, P < 0.001). Accordingly, subjects with cholesterol and/or triglyceride serum levels above 6.4 and 1.8 mmol/L, respectively, displayed a mean increase of 40% of their CYP2E1 activity vs subjects within the above values. It is believed that individuals with increased CYP2E1 activity are more susceptible to the adverse effects of CYP2E1-mediated activation of toxins and carcinogens.
authors.affiliation: Laboratoires de Biochimie-Nutrition, Faculté de Médecine de Brest, France.
authors.forename: D
authors.initials: D
authors.lastname: Lucas
authors.forename: C
authors.initials: C
authors.lastname: Farez
authors.forename: L G
authors.initials: LG
authors.lastname: Bardou
authors.forename: J
authors.initials: J
authors.lastname: Vaisse
authors.forename: J R
authors.initials: JR
authors.lastname: Attali
authors.forename: P
authors.initials: P
authors.lastname: Valensi
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D002753:Chlorzoxazone / Q000378:metabolism*; D019392:Cytochrome P-450 CYP2E1 / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000201:enzymology*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000201:enzymology*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000201:enzymology*; D005260:Female; D006801:Humans; D006900:Hydroxylation; D008297:Male; D008875:Middle Aged; D009765:Obesity; D013379:Substrate Specificity
chemical_list: D019392:Cytochrome P-450 CYP2E1; D002753:Chlorzoxazone